Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Cerebrolysin iconCerebrolysinSmall moleculeNo amino acid sequence. Icon reflects category theme only.

Cerebrolysin

CognitiveResearch
~2-4 hours half-life·Injection·3w on / 12w off

Also known as: CERE, FPF-1070

A 2025 meta-analysis of 14 randomized controlled trials (2,884 patients) confirmed that Cerebrolysin improves neurological recovery after ischemic stroke [1]. This porcine brain-derived peptide preparation mimics BDNF, NGF, GDNF, and CNTF, the body's own neurotrophic repair signals. It's approved in over 40 countries for stroke, TBI, and dementia, though not in the United States. The nootropic community treats it differently: healthy adults run 20-day IM courses at 5 mL/day for cognitive sharpness, memory consolidation, and lasting neuroplastic gains that reportedly peak weeks after the last injection.

What Is Cerebrolysin?

Fourteen randomized controlled trials. Nearly 3,000 stroke patients. Measurable neurological improvement confirmed by meta-analysis (Patel et al. 2025)[1]. That's the clinical foundation under Cerebrolysin (CAS 12656-61-0), a standardized extract of porcine brain proteins manufactured by EVER Neuro Pharma (EBEWE brand) in Austria.

The active fraction is roughly 25% low-molecular-weight neuropeptides and 75% free amino acids, produced through controlled enzymatic proteolysis. Those peptide fragments cross the blood-brain barrier and activate the same signaling cascades as BDNF, NGF, GDNF, and CNTF. In practical terms, it's a biological shortcut to neurotrophic factor activity without requiring gene therapy or recombinant proteins.

Clinical use spans stroke recovery, traumatic brain injury, Alzheimer's disease, and vascular dementia across more than 40 countries. Clinicians in Europe and Asia prescribe it routinely; the FDA has never approved it for any indication. The biological complexity of porcine brain hydrolysate makes standardized FDA-pathway approval extremely unlikely regardless of efficacy data.

In the biohacking community, Cerebrolysin occupies a unique position. Hundreds of detailed user reports on Longecity and r/Nootropics describe lasting cognitive gains from 20-day IM courses, with effects reportedly peaking 4 to 6 weeks after the final injection. The durability is the consistent theme; this isn't a stimulant-like acute boost. A separate meta-analysis of TBI trials (10 studies, N=8,749)[2] showed improved GCS and GOS scores. The catch: all major Alzheimer's RCTs were manufacturer-funded, and the IM dose community users favor (1,076 mg/day) sits well below the 2,152 to 6,456 mg/day IV range used in clinical trials.

How Cerebrolysin Works

The active peptide fraction in Cerebrolysin is small enough (under 10 kDa) to cross the blood-brain barrier through transcytosis and facilitated transport. Once inside the CNS, these fragments activate the PI3K/Akt and MAPK/ERK signaling pathways, the same cascades triggered by endogenous BDNF, NGF, GDNF, and CNTF.

Downstream, this does several things simultaneously. Anti-apoptotic proteins like Bcl-2 get upregulated while pro-apoptotic signals (caspase-3) get suppressed. Neurons that would otherwise die under oxidative stress or ischemic conditions survive. Neurite outgrowth accelerates; dendritic spine density in hippocampal and cortical neurons increases, which is the structural basis for the memory and cognitive improvements seen in trials.

Cerebrolysin also modulates acetylcholine, dopamine, and serotonin neurotransmission. That triple-system modulation underlies the reported improvements in memory consolidation, processing speed, and mood. On the neuroinflammation side, it inhibits microglial activation and downregulates pro-inflammatory cytokines (TNF-alpha, IL-1-beta). In ischemic tissue, it attenuates glutamate-induced excitotoxicity and scavenges reactive oxygen species. The multimodal nature of this mechanism is both its strength and the reason it's difficult to characterize in a single-target pharmacological framework.

Cerebrolysin Benefits

  • Cerebrolysin benefits center on neurotrophic repair, cognitive improvement, and neuroprotection across both clinical and community settings.
  • Stroke recovery confirmed by pooled data from 14 RCTs (N=2,884): statistically significant NIHSS improvement with a mean difference of +1.39 points (Patel et al. 2025)[1].
  • TBI outcomes improved across 10 studies involving 8,749 patients, with better GCS and GOS scores, though no effect on mortality was detected [2].
  • Memory consolidation and recall speed are the most consistently reported benefits in the nootropic community; users across Longecity's 200-page megathread describe lasting improvements that persist months after a 20-day course.
  • BDNF, NGF, GDNF, and CNTF pathway activation occurs acutely after injection, triggering synaptogenesis and dendritic spine remodeling that continues developing weeks post-course.
  • Neuroinflammation reduction through microglial inhibition and TNF-alpha/IL-1-beta suppression, confirmed in preclinical models and consistent with clinical improvement timelines.
  • Mild-to-moderate Alzheimer's disease: a pre-2024 meta-analysis [3] showed superiority over placebo on cognitive endpoints, though manufacturer funding across those trials warrants caution.

Cerebrolysin: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Moderate
Based on 12 key studies·Research only

Moderate-to-strong clinical evidence for acute ischemic stroke: 2025 meta-analysis [1] of 14 RCTs (N=2,884) showed significant NIHSS improvement (MD +1.39, p=0.020); functional independence trend was non-significant.

Dosing studied: 2,152–6,456 mg/day IV (clinical trials for stroke/AD); 1,076–2,152 mg/day IM or IV (community extrapolation)
Read the evidence (key study, limitations)

TBI evidence is positive but heterogeneous (10 studies, N=8,749; improved GCS/GOS, no effect on mortality)[2]. Alzheimer's disease: pre-2024 meta-analysis [3] showed superiority over placebo in mild-to-moderate AD, but all major RCTs carry manufacturer funding risk (EBEWE/Ever Pharma). No clinical trials in healthy adults for cognitive enhancement. The biological complexity of porcine brain hydrolysate precludes FDA approval regardless of efficacy.

Key Study

Patel et al. 2025, "Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 RCTs," Cureus. PMID 41018475. N=2,884; significant NIHSS improvement; no increase in serious adverse events or hemorrhagic transformation.

Limitations

No evidence in healthy adults: all RCTs used neurological patient populations. AD evidence base has documented manufacturer funding bias; no independent large-scale AD replication. IM route used in community is understudied: clinical trials predominantly use IV infusion. US lyophilized "cerebrolysin" is not the product studied in any RCT (all trials used EBEWE pharmaceutical ampoules). Short-duration trials limit long-term safety and efficacy conclusions.

Community Experience
Strong
4.0/5
Based on high: one of top-discussed injectable nootropics on r/Nootropics and Longecity (~200-page megathread)

One of the most consistently praised injectable nootropics in the community.

Community dosing: 1,076 mg/day (5 mL IM) for 20 days: dominant community protocol; some advanced users replicate clinical IV doses (10–30 mL/day)
Read the reports (what users report 5, common issues 7)

Users report acute cognitive enhancement during the course (Days 3–7) and lasting neuroplastic effects for 1–3 months post-course: the durability of effects is the most consistent theme across hundreds of Longecity and r/Nootropics reports. Primary use is cognitive enhancement and neuroprotection in healthy adults, not stroke/TBI recovery. IM at 5 mL/day is the dominant protocol.

What users report (5)
  • Mental clarity and cognitive processing speed: onset typically Days 3–7 of course
  • Memory consolidation and recall speed: most consistently cited benefit
  • Long-lasting post-course effects (1–3 months) attributed to structural neuroplastic changes
  • Mood elevation and a sense of cognitive "sharpness" on injection days
  • Neurological recovery in stroke/TBI users: viewed as strongest and most clinically validated use case
Common issues (7)
  • Cost: $300–500 per pharmaceutical-grade 20-day course: primary barrier for most users
  • IV infusion required above 5 mL: practical self-administration challenge; most community users stay at 5 mL IM for this reason
  • Sourcing: EBEWE pharmaceutical ampoules (imported) vs US lyophilized powder are not equivalent; the US powder carries significant authenticity uncertainty
  • Customs seizure risk when importing EBEWE ampoules into the US
  • Transient dizziness, warmth, and agitation: commonly reported in the first few days; usually resolves
  • Variable response: a meaningful subset of users report zero effect, often attributed to sub-pharmaceutical product quality or insufficient dose via IM route
  • Sleep disruption if dosed in afternoon or evening: stimulating effect
Partially Aligned

Science and community agree on core neurotrophic mechanisms (BDNF/NGF upregulation, synaptogenesis, neuroprotection). Divergence: community uses IM at 1,076 mg/day: below all clinical trial doses (2,152–6,456 mg/day IV). Community extends use to healthy cognitive enhancement with no RCT evidence in that population. The EBEWE vs. lyophilized sourcing split is a major practical divergence: 100% of clinical evidence uses EBEWE; community in the US often cannot access it.

Cerebrolysin Dosage Guide

ExtrapolatedDose extrapolated from European clinical trials and published neuroprotection research
LevelDose / InjectionFrequency
Beginner5 mLDaily
Moderate10 mLDaily
Aggressive20 mLDaily
Note:

Cerebrolysin comes as a ready-to-use solution at 215.2 mg/mL in EBEWE ampoules. No reconstitution, no BAC water, no mixing. Open the ampoule, draw, inject. That simplicity is rare for injectable nootropics.

For the standard 5 mL IM protocol: one EBEWE 5 mL ampoule equals exactly 1,076 mg. Use a standard 5 mL syringe (not an insulin syringe; the volume is too large). Deltoid injections work with 23 to 25 gauge, 1-inch needles. Gluteal injections need 21 to 23 gauge, 1 to 1.5 inches.

The thing most beginners miss: dose before 10 AM. Cerebrolysin has a real stimulating effect, and afternoon dosing wrecks sleep. Also, warm the ampoule to room temperature before drawing; cold solution stings more on injection.

A 20-day course at 5 mL/day requires 100 mL total, which is four boxes of five 5 mL ampoules. A full course runs roughly $270 to $300, including international shipping.

Store ampoules at 2 to 8 degrees Celsius. Don't freeze them. Once opened, use immediately; there are no preservatives.

Cycling Protocol

On Period
3 weeks
Off Period
12 weeks

Standard course is 10-21 consecutive daily injections followed by a 3-6 month break. Courses may be repeated 2-4 times per year. Clinical protocols for stroke use 10-day courses; Alzheimer protocols use 20-day courses.

Calculate your Cerebrolysin dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Cerebrolysin Protocols by Goal

beginnerCommunity20 days active + 3–6 month break; repeat 2–4x/year
Active Course
Wk 1–3 (20 consecutive days)
1,076 mg (5 mL) · Once daily · Intramuscular (deltoid or gluteal)
Off-Cycle
Wk 12–26 (3–6 months)
0 · None · N/A

Expected: Days 1–3: possible acute alertness boost on injection days. Days 4–7: improved mental energy and focus. Weeks 2–3: memory consolidation, faster recall, enhanced cognitive clarity. Post-course weeks 4–12: lasting neuroplastic benefits; many users report peak effects 1–2 months after completing the course.

Monitor: No bloodwork required at this dose for healthy adults. Track cognitive markers (focus, memory, verbal recall) weekly using a simple subjective log. Monitor injection sites for redness, swelling, or induration.

Who Uses Cerebrolysin?

Bryan Johnson
Bryan Johnson

Entrepreneur & Longevity Pioneer

Cerebrolysin is possibly the best neuro-enhancer I've done (subjectively). Can I do more?

1076 mg eod · subcutaneous
Bryan Johnson
Bryan Johnson
have published Cerebrolysin protocols with dosing

How to Use Cerebrolysin

  1. 1
    Wash hands thoroughly with soap and water

    Prepare your workspace with alcohol swabs, a 5 mL syringe, and the appropriate needle (23 to 25 gauge for deltoid; 21 to 23 gauge for gluteal).

  2. 2
    Remove one EBEWE 5 mL ampoule from refrigerator storage

    Allow it to warm to room temperature for 5 to 10 minutes. Inspect: the solution should be clear to slightly yellow. Discard if cloudy or discolored.

  3. 3
    Score and snap the ampoule at the colored dot

    Draw the full 5 mL (1,076 mg) into your syringe. Tap out air bubbles and express them.

  4. 4
    Swab the injection site with alcohol

    For deltoid: the fleshy outer part of the upper arm. For gluteal: the upper outer quadrant of the buttock.

  5. 5
    Insert the needle at a 90-degree angle

    Inject slowly over 30 to 60 seconds. Slow injection reduces site pain and dizziness.

  6. 6
    Step 6

    Withdraw the needle, apply gentle pressure with a clean swab. Rotate injection sites daily across the 20-day course.

  7. 7
    Step 7

    Remain seated for 10 to 15 minutes after injection, especially during the first 3 days when dizziness is most common.

For doses above 5 mL (requiring IV): dilute the Cerebrolysin volume into 100 to 250 mL of 0.9% sodium chloride. Administer via IV drip over 15 to 60 minutes. Never co-infuse with other medications. IV administration requires sterile technique and ideally a trained observer.

Alternative Routes

Intramuscular (IM)

Limited to 1,076 mg/day maximum; below all published clinical trial doses. Community-preferred for convenience.

Deltoid (23–25G, 1 inch) or gluteal (21–23G, 1–1.5 inch). Inject slowly. Do not exceed 5 mL per IM injection: tissue injury is confirmed above this volume.

Intravenous Infusion (IV)

All clinical trial doses (10–30 mL/day) require IV. No dose ceiling on IV route within studied ranges. Faster CNS delivery; more closely replicates trial conditions.

Dilute in 100–250 mL 0.9% NaCl. Infuse over 15–60 minutes. Must use a dedicated saline line: do NOT co-infuse with any other medications. Requires IV access, sterile technique, and ideally an observer for first sessions.

Cerebrolysin Stacking Protocols

Works With

Semax

Both upregulate BDNF and NGF; Semax (intranasal) is far simpler to administer and extends neurotrophic signaling between Cerebrolysin courses or during the course itself.

Semax 600 mcg intranasal daily during or between Cerebrolysin courses

Selank

Cognitive + anxiolytic complement; Selank adds anxiolytic and mood-stabilizing effects via GABAergic modulation, balancing any overstimulation from Cerebrolysin.

Selank 250–500 mcg intranasal daily during Cerebrolysin course

Noopept

Classic Longecity stack: racetam-like compound with BDNF/NGF upregulation and neuroprotective properties; commonly combined for additive cognitive enhancement.

10–30 mg oral 1–2x daily during course

Alpha-GPC

Cholinergic support: Cerebrolysin modulates acetylcholine neurotransmission; Alpha-GPC provides substrate to sustain cholinergic activity during course.

300–600 mg oral daily, taken with Cerebrolysin dose

Avoid

MAO Inhibitors (MAOIs)

Cerebrolysin modulates dopamine, serotonin, and norepinephrine pathways; concurrent MAOI use creates unpredictable and potentially dangerous neurotransmitter interactions.

Do not combine
Antiepileptic Drugs (AEDs)

Cerebrolysin is contraindicated in status epilepticus and severe seizure disorders. The interaction between Cerebrolysin and AEDs is unstudied; use in seizure-disorder patients requires neurological supervision.

IV Co-infusion with Other Medications

Physical incompatibility: Cerebrolysin must NOT be mixed in the same IV bag as other drugs including vitamins, cardiovascular agents, or balanced amino acid infusion solutions. Administer in a dedicated saline line only.

Do not combine

Estimated Cost

Brand Price
EBEWE / EVER Pharma pharmaceutical ampoules: ~$60/box (5 mL ×5 ampoules = 25 mL, or equivalent configurations; April 2026 price). A 20-day course at 5 mL/day requires 100 mL total = ~4 boxes at $60 each ≈ $240 per course.
Compounded
US lyophilized "cerebrolysin" powder: $50–160 per vial (30–60 mg lyophilized). NOTE: these are NOT bioequivalent to pharmaceutical EBEWE ampoules. Community consensus strongly disfavors the lyophilized powder for meaningful protocols.

Pricing updated 2026-04-09

Cerebrolysin Side Effects

MAO inhibitor interaction is the most serious safety concern. Cerebrolysin modulates dopamine, serotonin, and norepinephrine pathways simultaneously. Concurrent MAOI use creates unpredictable and potentially dangerous neurotransmitter accumulation. This combination should be avoided entirely.

Seizure risk is real for specific populations. Cerebrolysin is contraindicated in status epilepticus and severe seizure disorders. Patients on antiepileptic drugs should not use Cerebrolysin without neurological supervision, as the interaction between neurotrophic signaling and seizure thresholds has not been studied.

Porcine allergy is the other hard stop. Because the preparation is derived from pig brain tissue, anyone with a known allergy to porcine products faces genuine anaphylaxis risk. Hypersensitivity to any component of the preparation is a listed contraindication.

Published side effects from controlled clinical trials:

Dizziness and vertigo are the most commonly reported adverse events. In clinical trials, overall adverse event rates were comparable to placebo [4]. Community users report the worst dizziness occurs in the first 3 days and usually self-resolves. Injecting slowly (over 60 seconds) and staying seated for 10 to 15 minutes post-injection reduces the severity.

Headache, nausea, and sweating appear at rates consistent across the trial literature. These are more common with IV infusion at higher doses (10 to 30 mL/day) than with IM at 5 mL.

Agitation and a sensation of warmth are reported at higher IV doses. Community reports describe this as a stimulating quality that can disrupt sleep if dosed after midday.

Injection site reactions (pain, redness, swelling) occur with IM administration. Induration lasting beyond 48 hours or worsening should prompt medical evaluation.

Transient flu-like symptoms in the first few days of treatment have been reported in a minority of users.

SSRI and SNRI interaction monitoring is recommended. Cerebrolysin's serotonin modulation creates a theoretical risk of serotonergic excess when combined with antidepressants. Lithium levels should be monitored closely if co-administered.

For pregnancy and breastfeeding: insufficient safety data exists for injectable use. This is a contraindication.

When to stop: signs of porcine allergy (rash, urticaria, facial swelling), persistent agitation beyond 3 days, any seizure-like activity, or worsening neurological symptoms. When to see a doctor: any infusion reaction (flushing, chest tightness, breathing difficulty), injection site infection, or unexplained neurological changes during or after a course.

Common Issues & Solutions

No noticeable effect at 5 mL IM: This is the most common community complaint. Likely causes are sub-pharmaceutical product (lyophilized US versions), inadequate dose for the individual, or the IM route being insufficient: consider switching to IV infusion at 5–10 mL if using confirmed EBEWE ampoules.

Dizziness or vertigo in the first few days: Normal transient response. Inject slowly over 60+ seconds. Ensure morning dosing while seated or lying down for 10–15 minutes post-injection. Usually resolves by Day 3–4.

Sleep disruption and insomnia: Caused by the stimulating nootropic effect. Strict morning dosing (before 10 AM) is essential. Do not attempt afternoon or evening administration.

Injection site pain or induration (IM): Inject slowly; warm the ampoule to room temperature before drawing; use 23–25G for deltoid, 21–23G for gluteal. Rotate sites daily. Induration lasting more than 48 hours or increasing should prompt evaluation.

Sourcing anxiety (US users): EBEWE pharmaceutical ampoules are the only product validated in clinical evidence. Lyophilized products sold in the US are not bioequivalent porcine brain hydrolysate: the community consensus strongly disfavors these for any meaningful protocol. Personal importation of an unapproved drug carries customs seizure risk that must be weighed individually.

Ask AI about this page

Ask AI for a second opinion on Cerebrolysin dosing and side effects

Contraindications

  • Known allergy to porcine-derived products
  • Status epilepticus or severe seizure disorders
  • Severe renal impairment
  • Pregnancy and breastfeeding (injectable: insufficient safety data)
  • Hypersensitivity to any component of the preparation

Drug Interactions

  • MAO inhibitors: potential for unpredictable neurotransmitter interactions; avoid concurrent use
  • Antidepressants (SSRIs, SNRIs): monitor for serotonergic effects due to serotonin modulation
  • Lithium: possible pharmacodynamic interaction; monitor levels closely
  • Anticoagulants: no direct interaction established, but monitor as with any injectable
  • Cerebrolysin modulates dopamine, serotonin, and norepinephrine pathways; concurrent MAOI use creates unpredictable and potentially dangerous neurotransmitter interactions.

Product Quality

Recommended Monitoring

TestWhenTarget
Renal function (serum creatinine / eGFR)Before starting first course; annually if repeating courseseGFR >60 mL/min/1.73m² for unrestricted use; caution at 30–60; avoid below 30
Neurological status assessment (for stroke/TBI use)Baseline, Day 7, Day 14, Day 21, and 30/60/90 days post-courseNot listed
Cognitive self-assessment log (community use)Daily during course; weekly post-course for 3 monthsNot listed
Renal function (serum creatinine / eGFR)

Severe renal impairment is a contraindication: Cerebrolysin is renally cleared and accumulation risk is elevated with impaired GFR.

Neurological status assessment (for stroke/TBI use)

Track functional recovery using NIHSS (stroke) or GCS/GOS (TBI) to quantify treatment response against published benchmarks.

Cognitive self-assessment log (community use)

No validated biomarker for cognitive enhancement in healthy adults: subjective tracking of memory, focus, verbal fluency, and sleep quality is the primary endpoint for community protocols.

Cerebrolysin Before and After

Days 1-7

Initial neuroprotective effects begin. Some users report improved alertness and mental energy within the first week.

Weeks 2-3

Improved mental clarity, focus, and working memory. Neurotrophic signaling pathways are upregulated.

Week 3

Peak cognitive benefits: enhanced memory consolidation, faster recall, and improved attention span. End of standard course.

Post-course
months 1-3

Benefits persist for weeks to months after completing a course due to structural neuroplastic changes (increased synaptic density).

What to Expect

Days 1 to 3: Neuroprotective signaling kicks in immediately. BDNF and neurotrophic pathways upregulate with the first doses. Community users describe a pronounced mental sharpness or "brain reboot" feeling, sometimes within hours. This is also when transient dizziness, warmth, mild agitation, and headache are most likely; they typically resolve by Day 3 or 4 without intervention.

Days 4 to 7: Sustained neurotrophic factor activity is building. Synaptogenesis signaling starts, and neuroinflammation begins to decrease. Users report improved mental energy, faster processing speed, and better verbal fluency. Working memory improvements become noticeable. The acute "sharpness" from injection days starts settling into something more baseline.

Weeks 2 to 3: This is the peak window during the active course. Clinical trial data shows significant NIHSS improvement in stroke patients and ADAS-cog gains in Alzheimer's patients within this timeframe. Community users describe their best cognitive performance here: stronger memory consolidation, faster recall, reduced cognitive fatigue. Many report this as the best their brain has felt in years.

Post-course, weeks 4 to 8: The course is over, but the biology isn't finished. Structural neuroplastic changes (synaptic density increases, dendritic spine remodeling) continue developing as the biological result of upregulated BDNF and NGF. Many users report peak effects arriving 4 to 6 weeks after the last injection. Benefits feel less like an acute boost and more like a genuine shift in baseline cognition.

Post-course, months 2 to 3: Neuroplastic benefits plateau. Endogenous neurotrophic factor levels drift back toward baseline while the structural changes persist. Most users describe a lasting upward shift in cognitive baseline. Some fading becomes noticeable by month 3, which is the typical signal that it's time to consider repeating the course after the minimum 3-month break.

Detailed Timeline: Science vs Community

Days 1–3
Science

Neuroprotective mechanisms begin; BDNF and neurotrophic signaling pathways upregulated acutely after first doses.

Community

Pronounced acute effect on injection days described as mental sharpness or a "brain reboot" sensation. Some users report feeling the injection within minutes to hours.

Days 4–7
Science

Sustained neurotrophic factor upregulation; synaptogenesis signaling initiating; neuroinflammation reduction beginning.

Community

Improved mental energy, processing speed, and verbal fluency. Working memory improvements beginning. The "sharpness" from injection days becoming more baseline.

Weeks 2–3
Science

Clinical trial data (NIHSS improvement in stroke; ADAS-cog improvement in AD) reaches significance in this window for most studied indications. Peak neurotrophic signaling.

Community

Memory consolidation and recall speed improvements peak. Enhanced attention span and reduced cognitive fatigue. Many users describe this as the best their brain has felt in years.

Post-Course (Weeks 4–8)
Science

Structural neuroplastic changes (increased synaptic density, dendritic spine remodeling) continue to develop post-course as the biological substrate of upregulated BDNF/NGF.

Community

Many users report peak effects arriving 4–6 weeks after the last injection: not during the course itself. Benefits feel "more real" and integrated into baseline cognition.

Post-Course (Months 2–3)
Science

Neuroplastic benefits plateau; endogenous neurotrophic factor levels return toward baseline while structural changes persist.

Community

Lasting cognitive improvement that most users describe as a permanent upward shift in baseline: though some fading is noted by month 3, which is the typical rationale for repeating the course.

Pharmacokinetics

Half-Life
3h
Bioavailability
IM: ~100% (direct parenteral), IV: 100%
Tmax
IM: ~30-60 minutes (estimated from peptide absorption kinetics)
Data Confidence
low

Source: Estimated from peptide component kinetics; composite mixture effect ~2-4 hours

Pharmacokinetics: Active Dose Over Time

t½ = ~2-4 hours

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Who Should Consider Cerebrolysin

  • Stroke recovery patients
  • Individuals with mild-to-moderate Alzheimer's disease
  • Traumatic brain injury recovery
  • Vascular dementia patients
  • Adults seeking cognitive enhancement and neuroprotection
  • Aging individuals concerned about neurodegenerative decline

Related Peptides

What Changed for Cerebrolysin

  1. Dosing

    Corrected Oct 9, 2026: cerebrolysin tiers now read 5, 10 and 20 mL of solution, the unit trials dose it in, per ClinicalTrials.gov NCT00911807.

    Before: Tiers of 1,076, 2,152 and 4,304 mg daily (unit mg) After: Tiers of 5, 10 and 20 mL daily of the 215.2 mg/mL solution (the same amounts, in mL)

    Source: ClinicalTrials.gov NCT00911807, Cerebrolysin 10 mL IV infusions in Alzheimer disease (API v2 record) (opens in a new tab) · Saved copy

Peptide Schedule Research TeamReviewed Apr 7, 202612 Citations

References

  1. [1]Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 RCTs (Patel et al., Cureus 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Cerebrolysin in patients with TBI: systematic review and meta-analysis (Jarosz et al., Brain Sci 2023) (opens in a new tab)(N=8,749)PubMed (opens in a new tab)PubMed
  3. [3]Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Resources

Related Tools

Storage & Stability

Before Reconstitution
Not applicable: pre-filled solution, no reconstitution required
After Reconstitution
Not applicable: use directly from vial or ampoule
Temperature
2-8°C (36-46°F), protect from light. Do not freeze.

Frequently Asked Questions

EBEWE (Ever Pharma, Austria) manufactures the original pharmaceutical product; a 215.2 mg/mL solution of standardized porcine brain hydrolysate. US research-grade "cerebrolysin" is typically a lyophilized powder that may be synthetic peptide fractions, not the full biological extract. Experienced community users specifically seek EBEWE and consider lyophilized versions unvalidated substitutes.

No. IM injection is limited to volumes of ≤5 mL (≤1,076 mg). Above 5 mL, the preparation must be diluted in 100–250 mL of 0.9% saline and administered as a slow IV infusion over 15–60 minutes. Attempting IM injection of >5 mL causes local tissue injury.

Yes. The low-molecular-weight peptide fraction (<10 kDa) crosses the BBB via transcytosis and facilitated transport. This is one of Cerebrolysin's distinguishing properties compared to most large-molecule neurotrophic factors, which cannot cross the BBB.

Clinical observations and community reports consistently describe effects persisting for weeks to months post-course, attributed to structural neuroplastic changes (increased synaptic density, BDNF upregulation). This is the rationale for the 3–6 month break between courses.

Long-term safety data comes from 50+ country clinical use and ~658 published papers. Adverse event rates in controlled trials were comparable to placebo. The main unresolved issue is that many supporting RCTs were funded by the manufacturer. No long-term toxicity signal has emerged in post-marketing surveillance across decades of clinical use.